Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.57 |
| ▸ | MAPT | P10636 | 4/20 | 0.52 |
| ▸ | TP53 | P04637 | 4/20 | 0.43 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | RAB9A | P51151 | 3/20 | 0.38 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL548231 | 0.71 | POLB (0.69) | POLBMAPTTP53SMN1; SMN2ALDH1A1 | |
| SCHEMBL548339 | 0.69 | POLB (0.62) | POLBMAPTTP53SMN1; SMN2RAB9A | |
| SCHEMBL10016318 | 0.69 | MAPT (1.00) | POLBMAPTTP53SMN1; SMN2TSHR | |
| SCHEMBL548302 | 0.68 | POLB (0.69) | POLBMAPTTP53SMN1; SMN2ALDH1A1 | |
| SCHEMBL549133 | 0.68 | POLB (0.67) | POLBMAPTTP53SMN1; SMN2ALDH1A1 | |
| SCHEMBL549116 | 0.68 | POLB (0.54) | POLBMAPTPTGS2KDM4EALDH1A1 | |
| SCHEMBL549105 | 0.68 | POLB (0.54) | POLBMAPTTP53PTGS2KDM4E | |
| SCHEMBL6352561 | 0.67 | RAB9A (0.61) | POLBMAPTTP53PTGS2SMN1; SMN2 | |
| SCHEMBL548181 | 0.67 | POLB (0.59) | POLBMAPTTP53SMN1; SMN2KDM4E | |
| SCHEMBL23405497 | 0.61 | POLB (0.62) | POLBMAPTTP53PTGS2SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100222398-A1 | NOVEL 1,2,3-TRIAZOLE DERIVATIVES USEFUL AS MODULATORS OF NICOTINIC ACETYLCHOLINE RECEPTORS | NEUROSEARCH A/S (DK) | 2010-09-02 | — | — | US | claimed |
| US-8110588-B2 | 1,2,3-triazole derivatives useful as modulators of nicotinic acetylcholine receptors | NEUROSEARCH A/S (DK) | 2012-02-07 | — | — | US | disclosed |
| US-20100222398-A1 | NOVEL 1,2,3-TRIAZOLE DERIVATIVES USEFUL AS MODULATORS OF NICOTINIC ACETYLCHOLINE RECEPTORS | NEUROSEARCH A/S (DK) | 2010-09-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100222398-A1 | NOVEL 1,2,3-TRIAZOLE DERIVATIVES USEFUL AS MODULATORS OF NICOTINIC ACETYLCHOLINE RECEPTORS | CHRNA3, CHRNB3, CHRNA5 | POLB 4113/4885MAPT 700/4885TP53 4840/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.